Get to know our clinical trials
A study to evaluate the efficacy and safety of Rina-S in participants with non-small cell lung cancer.
THE GOAL IS TO CONTINUOUSLY MONITOR YOUR WELL-BEING AND SAFETY, AND TO ASK YOU IF YOU HAVE STARTED A NEW TREATMENT. IF, FOR ANY REASON, THE DOCTOR OR TRIAL STAFF ARE UNABLE TO CONTACT YOU, A FAMILY MEMBER MAY PROVIDE INFORMATION ABOUT YOUR CONDITION, OR THE TRIAL DOCTOR MAY OBTAIN IT FROM SOURCES SUCH AS YOUR MEDICAL RECORDS, NATIONAL OR LOCAL REGISTRIES, OR PUBLICLY AVAILABLE INFORMATION, AS PERMITTED BY LOCAL REGULATIONS.
Technical Summary
- AN OPEN-LABEL, PHASE II, MULTICENTER STUDY OF RINATABART SESUTECAN (RINA-S) IN PARTICIPANTS WITH NON-SMALL CELL LUNG CANCER.
- Code EudraCT: 2025-522107-18-00
- Protocol number: GCT1184-05
- Promoter: Genmab A/S
- Molecule/Drug: Rina-S
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.